ArticleCell reports2016
Transplantation Dose Alters the Differentiation Program of Hematopoietic Stem Cells.
Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Mapping Hematopoietic Fate after Transplantation.Stem cell reviews and reports · 2025Review
- Advancements in prospective single-cell lineage barcoding and their applications in research.Genome research · 2024Review
- Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies.Hematology, transfusion and cell therapy · 2024Article
- Age-associated imbalance in immune cell regeneration varies across individuals and arises from a distinct subset of stem cells.Cellular & molecular immunology · 2024Article
- Quantitative association between gene expression and blood cell production of individual hematopoietic stem cells in mice.Science advances · 2024Article
- Lineage tracking to reveal the fate of hematopoietic stem cells influenced by Flk2Experimental & molecular medicine · 2023Article
- Stem Cells, Hematopoiesis and Lineage Tracing: Transplantation-Centric Views and Beyond.Frontiers in cell and developmental biology · 2022Review
- A single-cell resolved cell-cell communication model explains lineage commitment in hematopoiesis.Development (Cambridge, England) · 2021Article
- Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses.Nature communications · 2021Article
- Longitudinal clonal tracking in humanized mice reveals sustained polyclonal repopulation of gene-modified human-HSPC despite vector integration bias.Stem cell research & therapy · 2021Article
- Clonal tracking using embedded viral barcoding and high-throughput sequencing.Nature protocols · 2020Article
- Clonal-level lineage commitment pathways of hematopoietic stem cells in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Functional compensation between hematopoietic stem cell clonesEMBO reports · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hematopoietic stem cell (HSC) transplantation is the most prevalent stem cell therapy, but it remains a risky procedure. To improve this treatment, it is important to understand how transplanted stem cells rebuild the blood and immune systems and how this process is impacted by transplantation variables such as the HSC dose. Here, we find that, in the long term following transplantation, 70%-80% of donor-HSC-derived clones do not produce all measured blood cell types. High HSC doses lead to more clones that exhibit balanced lymphocyte production, whereas low doses produce more T-cell-specialized clones. High HSC doses also produce significantly higher proportions of early-differentiating clones compared to low doses. These complex differentiation behaviors uncover the clonal-level regeneration dynamics of hematopoietic regeneration and suggest that transplantation dose can be exploited to improve stem cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.